Rice Hall James & Associates’s Y-mAbs Therapeutics YMAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-109,604
| Closed | -$494K | – | 258 |
|
|
2025
Q2 | $494K | Buy |
109,604
+5,962
| +6% | +$26.8K | 0.03% | 220 |
|
|
2025
Q1 | $459K | Sell |
103,642
-4,907
| -5% | -$28.5K | 0.03% | 224 |
|
|
2024
Q4 | $850K | Sell |
108,549
-135
| -0.1% | -$1.64K | 0.05% | 207 |
|
|
2024
Q3 | $1.43M | Buy |
108,684
+18,949
| +21% | +$240K | 0.08% | 193 |
|
|
2024
Q2 | $1.08M | Buy |
89,735
+3,589
| +4% | +$48.5K | 0.07% | 206 |
|
|
2024
Q1 | $1.4M | Buy |
86,146
+633
| +0.7% | +$8.53K | 0.08% | 196 |
|
|
2023
Q4 | $583K | Sell |
85,513
-5,736
| -6% | -$33.2K | 0.03% | 238 |
|
|
2023
Q3 | $497K | Sell |
91,249
-1,773
| -2% | -$10.3K | 0.03% | 239 |
|
|
2023
Q2 | $632K | Buy |
93,022
+3,542
| +4% | +$26.5K | 0.04% | 236 |
|
|
2023
Q1 | $448K | Buy |
89,480
+2,390
| +3% | +$9.76K | 0.03% | 246 |
|
|
2022
Q4 | $425K | Sell |
87,090
-3,575
| -4% | -$26K | 0.02% | 249 |
|
|
2022
Q3 | $1.31M | Sell |
90,665
-1,233
| -1% | -$20.4K | 0.08% | 221 |
|
|
2022
Q2 | $1.39M | Buy |
91,898
+1,523
| +2% | +$17.8K | 0.07% | 223 |
|
|
2022
Q1 | $1.07M | Buy |
90,375
+5,980
| +7% | +$61.4K | 0.04% | 239 |
|
|
2021
Q4 | $1.37M | Sell |
84,395
-14,896
| -15% | -$318K | 0.05% | 231 |
|
|
2021
Q3 | $2.83M | Buy |
99,291
+2,517
| +3% | +$79.3K | 0.1% | 152 |
|
|
2021
Q2 | $3.27M | Sell |
96,774
-4,254
| -4% | -$137K | 0.12% | 131 |
|
|
2021
Q1 | $3.06M | Buy |
101,028
+34
| +0% | +$1.39K | 0.1% | 144 |
|
|
2020
Q4 | $5M | Buy |
100,994
+6,427
| +7% | +$297K | 0.18% | 102 |
|
|
2020
Q3 | $3.63M | Buy |
94,567
+30,241
| +47% | +$1.2M | 0.15% | 116 |
|
|
2020
Q2 | $2.78M | Buy |
64,326
+698
| +1% | +$26.4K | 0.12% | 129 |
|
|
2020
Q1 | $1.66M | Buy |
63,628
+24,062
| +61% | +$699K | 0.09% | 155 |
|
|
2019
Q4 | $1.24M | Buy |
+39,566
| New | +$1.17M | 0.04% | 221 |
|
Other funds holding YMAB
Rice Hall James & Associates's YMAB Position: Q3 2025 in Review
Rice Hall James & Associates sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 109,604 shares — an estimated $494K sold.
Rice Hall James & Associates first reported a position in YMAB in Q4 2019 and held it in 23 quarters. The position peaked at $5M in Q4 2020. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.
- Rice Hall James & Associates reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
- Rice Hall James & Associates sold 109,604 Y-mAbs Therapeutics shares in Q3 2025, an estimated $494K.
- Rice Hall James & Associates first reported a position in Y-mAbs Therapeutics in Q4 2019 and held it in 23 quarters.
- Rice Hall James & Associates's Y-mAbs Therapeutics position peaked at $5M in Q4 2020.
- 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.
Based on Rice Hall James & Associates's 13F filing for Q3 2025, filed 16 Oct 2025.